Page 39 - அமெரிக்கன் சமூகம் ஆஃப் ஹீமாட்டாலஜி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MaaT Pharma to Provide Clinical Data for Lead Microbiome Ecosystem Therapeutic MaaT013 in Intestinal Acute GvHD at Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

MaaT Pharma to Provide Clinical Data for Lead Microbiome Ecosystem Therapeutic MaaT013 in Intestinal Acute GvHD at Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) Topline data from the Phase 2 HERACLES clinical trial with MaaT013 will be announced near-term MaaT Pharma announced today that data from its early access program for lead microbiome ecosystem therapeutic, MaaT013, will be reported in an oral presentation at the virtual 47 th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) taking place from March 14 March 17, 2021. The data was previously presented at the American Society of Hematology in December 2020. MaaT013 is an enema formulation of a full ecosystem microbiota biotherapeutic characterized by a consistent high diversity and richness of microbial species derived from pooled healthy donors The results include data from 29 patients with gastrointestinal, acute Graft-versus-Host-Disea

United statesMicrobiota biotherapeuticKostenloser wertpapierhandelFlorent malardLaura mittmannAmerican society of hematologySorbonne universityEuropean medicines agencyDrug administrationTrophic communicationsMeeting of the european society for bloodCompassionate use expanded access treatment programGraft versus host diseaseAnnual meetingEuropean societyMarrow transplantation

Geron Corporation Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

Share: Conference Call Scheduled for 4:30 p.m. ET today Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies, today reported financial results for the fourth quarter and year ended December 31, 2020. The Company ended fiscal year 2020 with $260 million in cash and marketable securities, which is expected to fund operations until the end of 2022. Geron s vision is to be recognized as a leader in the treatment of hematologic malignancies by changing the course of these diseases and thereby improving and extending the lives of patients, said John A. Scarlett, M.D., Chairman and Chief Executive Officer. In 2020, we made important progress toward realizing that vision through two ongoing Phase 3 clinical trials, presentation of new data and analyses providing strong evidence of imetelstat s disease-modifying potential that differentiates imetelstat from

United statesJohna scarlettAsterias biotherapeutics incGeron corporationDrug administrationData monitoring committeeExchange commissionAmerican society of hematologyLineage cell therapeutics incBiotime incConference call scheduledChief executiveLower risk myelodysplastic syndromesIndependent data monitoring committeeRefractory myelofibrosisNorth america

Poseida Therapeutics Reports Program Updates and Financial Results for the Fourth Quarter and Full Year 2020

Poseida Therapeutics Reports Program Updates and Financial Results for the Fourth Quarter and Full Year 2020 News provided by Share this article Share this article SAN DIEGO, March 11, 2021 /PRNewswire/ Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the fourth quarter and full year ended December 31, 2020. 2020 was a transformative year for Poseida, as we completed our IPO and became a public company all while advancing multiple programs and substantially expanding the application of our core technologies, enabling us to engineer a portfolio of product candidates designed to overcome the limitations of current cell and gene therapeutics, said Eric Ostertag, M.D., Ph.D., Chief Executive Officer of Poseida. This important progress was on display in lat

United statesEric ostertagDc programPoseida therapeutics incCompany rd dayAmerican society of hematologyDevelopment expensesExchange commissionProgram updatesPoseida therapeuticsChief executive officerAmerican societyAnnual meetingEmerging discoverySpecific gene editingFourth quarter

أطباء مصريين : أكثر من ثلث المرضى يصابون بجلطات دموية و20-30% من وفيات كورونا نتيجة مضاعفات القلب

أطباء مصريين : أكثر من ثلث المرضى يصابون بجلطات دموية و20-30% من وفيات كورونا نتيجة مضاعفات القلب
almogaz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from almogaz.com Daily Mail and Mail on Sunday newspapers.

United statesMuhammad abdul hakimAmerican society of hematologyAmerican societyஒன்றுபட்டது மாநிலங்களில்அமெரிக்கன் சமூகம் ஆஃப் ஹீமாட்டாலஜிஅமெரிக்கன் சமூகம்

Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update Regulatory guidance anticipated in the first half of 2021 for registrational clinical development plan of investigational drug, rusfertide (PTG-300), for polycythemia vera Company expects to share findings from ongoing hereditary hemochromatosis study for rusfertide (PTG-300) in the second half of 2021 Strong cash position to fund planned operations through the first half of 2024 Management to host conference call today at 4:30 p.m. EST News provided by Share this article Share this article NEWARK, Calif., March 10, 2021 /PRNewswire/ Protagonist Therapeutics, Inc. ( Protagonist or the Company ) (Nasdaq: PTGX) today reported financial results and provided a corporate update for the fourth quarter and full year ended December 31, 2020.

United statesDineshv patelCompany nasdaqPrnewswire protagonist therapeutics incDrug administrationProtagonist therapeutics incAmerican society of hematologyExchange commissionDevelopment rd expensesEuropean medicines agencyProtagonist presidentChief executiveFast trackRed blood cellsAmerican societyCash equivalents